Mr. Thomas Smeenk reports

HEMOSTEMIX CLARIFIES ITS OCTOBER 3, 2023 NEWS RELEASE

Hemostemix Inc. is clarifying its press release of Oct. 3, 2023. It referred to the private placement of $320,125. The company closed the financing in the amount of $320,385 with the issuance of 2,669,875 units. In connection with that offering, the corporation paid eligible finders aggregate fees of $5,750.40 in cash and issued 47,920 finder options to purchase common shares of the corporation, at an exercise price of 12 cents per common share within 24 months from the closing of the offering.

The board of directors has authorized the issuance of 2,375,000 stock options at seven each, to directors, officers and consultants of the company.

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the company has developed, patented and is scaling a patient's blood-based stem cell therapeutics platform that includes angiogenic cell precursors, neuronal cell precursor and cardiomyocyte cell precursors.

We seek Safe Harbor.